Cargando…

SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis

Detalles Bibliográficos
Autores principales:	Kirchner, Theresa, Jaeckel, Elmar, Falk, Christine S., Eiz-Vesper, Britta, Taubert, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285931/ https://www.ncbi.nlm.nih.gov/pubmed/34284030 http://dx.doi.org/10.1016/j.jhep.2021.07.012

Ejemplares similares

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation-a prospective six month follow-up
por: Kirchner, Theresa, et al.
Publicado: (2022)

Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19
por: Kirchner, Theresa, et al.
Publicado: (2022)

No association of serum ferritin levels with advanced liver fibrosis in untreated German patients with autoimmune hepatitis
por: Engel, Bastian, et al.
Publicado: (2022)

Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy
por: Diestelhorst, Jana, et al.
Publicado: (2017)

Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis
por: Diestelhorst, Jana, et al.
Publicado: (2018)

HSP70 Enhances Immunosuppressive Function of CD4(+)CD25(+)FoxP3(+) T Regulatory Cells and Cytotoxicity in CD4(+)CD25(−) T Cells
por: Wachstein, Julian, et al.
Publicado: (2012)

Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis
por: Taubert, Richard, et al.
Publicado: (2017)

Selective Effects of mTOR Inhibitor Sirolimus on Naïve and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression
por: Bak, Szilvia, et al.
Publicado: (2018)

Salvage therapies of autoimmune hepatitis limit proinflammatory immune cells while sparing regulatory T cells
por: Derben, Finn C., et al.
Publicado: (2023)

Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry
por: Eiz-Vesper, Britta, et al.
Publicado: (2013)

Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis
por: Taubert, Richard, et al.
Publicado: (2018)

Use of Convalescent/ Post-Vaccination Plasma in Immunosuppressed Patients with Persistent Sars-Cov-2 Infection
por: Pedraza, Alexandra, et al.
Publicado: (2022)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Disease course in patients with systemic autoimmune diseases: insights on the safety of immunosuppression during the SARS-CoV-2 outbreak in Italy
por: Benfaremo, Devis, et al.
Publicado: (2021)

Increased apoptosis of regulatory T cells in patients with active autoimmune hepatitis
por: John, Katharina, et al.
Publicado: (2017)

Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality
por: Rocco, Alba, et al.
Publicado: (2021)

Dynamics of faecal SARS-CoV-2 in infected children during the convalescent phase
por: Xing, Yuhan, et al.
Publicado: (2020)

Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
por: Franchini, Massimo, et al.
Publicado: (2021)

Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
por: Gussarow, Daniel, et al.
Publicado: (2021)

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients
por: Koldehoff, Michael, et al.
Publicado: (2023)

Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty?
por: Londoño, Maria-Carlota, et al.
Publicado: (2021)

Persistence of anti-SARS-CoV-2 IgM in convalescent COVID-19 patients
por: Yan, Xiquan, et al.
Publicado: (2021)

Enhancement of Antiviral T-Cell Responses by Vitamin C Suggests New Strategies to Improve Manufacturing of Virus-Specific T Cells for Adoptive Immunotherapy
por: Laubert, Miriam, et al.
Publicado: (2022)

Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium
por: Verhelst, Xavier, et al.
Publicado: (2021)

Plasma from donors convalescent from SARS-CoV-2 infection–A matter of priorities
por: Farrugia, A.
Publicado: (2020)

Convalescent plasma therapy for persistent hepatitis E virus infection
por: Ankcorn, Michael, et al.
Publicado: (2019)

Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy
por: Bonifacius, Agnes, et al.
Publicado: (2022)

Robust Identification of Suitable T-Cell Subsets for Personalized CMV-Specific T-Cell Immunotherapy Using CD45RA and CD62L Microbeads
por: Mangare, Caroline, et al.
Publicado: (2019)

Splenectomy induces biochemical remission and regeneration in experimental murine autoimmune hepatitis
por: Dywicki, Janine, et al.
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma/immunosuppressants: SARS-CoV-2 infection, its re-infection and off label use: case report
Publicado: (2021)

Use of convalescent plasma in COVID‐19 patients with immunosuppression
por: Senefeld, Jonathon W., et al.
Publicado: (2021)

Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy
por: Schillingmann, Damaris A., et al.
Publicado: (2019)

Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report
por: Wicklein, Rebecca, et al.
Publicado: (2021)

Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma
por: Tonn, Torsten, et al.
Publicado: (2020)

The association between micronutrients and the SARS-CoV-2-specific antibodies in convalescent patients
por: Panahibakhsh, Maryam, et al.
Publicado: (2022)

SARS-CoV-2-specific immune response in COVID-19 convalescent individuals
por: Pan, Yunbao, et al.
Publicado: (2021)

Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies
por: Tischer, Sabine, et al.
Publicado: (2011)

Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes
por: Bieling, Maren, et al.
Publicado: (2017)

Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge
por: Ma, Huan, et al.
Publicado: (2020)

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
por: Mika, Thomas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j8kc9t9nobdimuqh86neak2784